A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
Completed · Phase 2 · Has a placebo group
Conditions studied: Liver Fibrosis, Hepatic Cirrhosis
In brief
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body
Key facts
- Study ID
- NCT06750276
- Run by
- AstraZeneca
- People needed
- 40
- Starts
- 2024-12-06
- Expected to finish
- 2025-07-28
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Chandler, Arizona, United States
- Research Site — Rialto, California, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Morehead City, North Carolina, United States
- Research Site — Houston, Texas, United States
- Research Site — San Antonio, Texas, United States
- Research Site — San Antonio, Texas, United States
- Research Site — San Juan, Puerto Rico
- Research Site — Cambridge, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.